Ocular Therapeutix (OCUL) Gains from Investment Securities (2013 - 2026)
Ocular Therapeutix's quarterly Gains from Investment Securities came in at -$4.9 million in Q1 2026, down 564.03% year-on-year from $1.0 million in Q1 2025, and down 126.52% quarter-over-quarter from $18.3 million in Q4 2025.
Ocular Therapeutix has reported Gains from Investment Securities for 14 years, with the latest figure at -$4.9 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 564.03% year-over-year to -$4.9 million; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (up 1214.67% YoY), and the FY2025 full-year result was $1.7 million, down 91.58% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$4.9 million, down from $18.3 million in the prior quarter.
- The five-year high for Gains from Investment Securities was $19.9 million in Q4 2024, with the low at -$4.9 million in Q1 2026.
- Average Gains from Investment Securities over 5 years is $2.7 million, with a median of $638477.5 recorded in 2023.
- Year-over-year, Gains from Investment Securities surged 27368.75% in 2023 and sank 564.03% in 2026.
- Tracing OCUL's Gains from Investment Securities over 5 years: stood at $212150.0 in 2022, then increased by 29.15% to $274000.0 in 2023, then jumped by 7158.28% to $19.9 million in 2024, then declined by 7.74% to $18.3 million in 2025, then tumbled by 126.52% to -$4.9 million in 2026.
- The last three Gains from Investment Securities figures came in at -$4.9 million (Q1 2026), $18.3 million (Q4 2025), and $262429.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ocular Therapeutix | 1.99 Bn | 1.99 Bn | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.87 Mn |
| Mar 31, 2026 | -4.87 Mn |
| Dec 31, 2025 | 18.35 Mn |
| Dec 31, 2025 | 18.35 Mn |
| Sep 30, 2025 | 262,429.00 |
| Sep 30, 2025 | 262,429.00 |
| Jun 30, 2025 | 29,000.00 |
| Jun 30, 2025 | 29,000.00 |
| Mar 31, 2025 | 1.05 Mn |
| Mar 31, 2025 | 1.05 Mn |
| Dec 31, 2024 | 19.89 Mn |
| Dec 31, 2024 | 19.89 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Sep 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 731,580.00 |
| Jun 30, 2024 | 731,580.00 |
| Mar 31, 2024 | 994,099.00 |
| Mar 31, 2024 | 994,099.00 |
| Dec 31, 2023 | 274,000.00 |
| Dec 31, 2023 | 274,000.00 |
| Sep 30, 2023 | 1.08 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 3.24 Mn |
| Jun 30, 2023 | 3.24 Mn |
| Mar 31, 2023 | 545,375.00 |
| Mar 31, 2023 | 545,375.00 |
| Sep 30, 2022 | 212,150.00 |
| Sep 30, 2022 | 212,150.00 |
| Jun 30, 2022 | 120,404.00 |
| Jun 30, 2022 | 120,404.00 |
| Mar 31, 2022 | -2,000.00 |
| Mar 31, 2022 | -2,000.00 |
| Dec 31, 2021 | 6.78 Mn |
| Dec 31, 2021 | 6.78 Mn |
| Jun 30, 2021 | 456,334.00 |
| Jun 30, 2021 | 456,334.00 |
| Mar 31, 2021 | 731,596.00 |
| Mar 31, 2021 | 731,596.00 |
| Dec 31, 2020 | 9.11 Mn |
| Dec 31, 2020 | 9.11 Mn |
| Sep 30, 2020 | 1.01 Mn |
| Sep 30, 2020 | 1.01 Mn |
| Jun 30, 2020 | 446,000.00 |
| Jun 30, 2020 | 446,000.00 |
| Mar 31, 2020 | 1.69 Mn |
| Mar 31, 2020 | 1.69 Mn |
| Dec 31, 2019 | -1.99 Mn |
| Dec 31, 2019 | -1.99 Mn |
| Sep 30, 2019 | 2.98 Mn |
| Sep 30, 2019 | 2.98 Mn |
| Jun 30, 2019 | 863,544.00 |
| Jun 30, 2019 | 863,544.00 |
| Mar 31, 2019 | 2.29 Mn |
| Mar 31, 2019 | 2.29 Mn |
| Dec 31, 2018 | 5.23 Mn |
| Dec 31, 2018 | 5.23 Mn |
| Sep 30, 2018 | 1.65 Mn |
| Sep 30, 2018 | 1.65 Mn |
| Jun 30, 2018 | 453,824.00 |
| Jun 30, 2018 | 453,824.00 |
| Mar 31, 2018 | 482,965.00 |
| Mar 31, 2018 | 482,965.00 |
| Dec 31, 2017 | 403,000.00 |
| Dec 31, 2017 | 403,000.00 |
| Sep 30, 2017 | 1.89 Mn |
| Sep 30, 2017 | 1.89 Mn |
| Jun 30, 2017 | 1.37 Mn |
| Jun 30, 2017 | 1.37 Mn |
| Mar 31, 2017 | 388,336.00 |
| Mar 31, 2017 | 388,336.00 |
| Dec 31, 2016 | -1.27 Mn |
| Dec 31, 2016 | -1.27 Mn |
| Sep 30, 2016 | 1.47 Mn |
| Sep 30, 2016 | 1.47 Mn |
| Jun 30, 2016 | 299,342.00 |
| Jun 30, 2016 | 299,342.00 |
| Mar 31, 2016 | 329,843.00 |
| Mar 31, 2016 | 329,843.00 |
| Dec 31, 2015 | 3.19 Mn |
| Dec 31, 2015 | 3.19 Mn |
| Sep 30, 2015 | 1.46 Mn |
| Sep 30, 2015 | 1.46 Mn |
| Jun 30, 2015 | 218,730.00 |
| Jun 30, 2015 | 218,730.00 |
| Mar 31, 2015 | 1.50 Mn |
| Mar 31, 2015 | 1.50 Mn |
| Dec 31, 2014 | 327,000.00 |
| Dec 31, 2014 | 327,000.00 |
| Sep 30, 2014 | -276,000.00 |
| Sep 30, 2014 | -276,000.00 |
| Jun 30, 2014 | 92,494.00 |
| Jun 30, 2014 | 92,494.00 |
| Mar 31, 2014 | 141,000.00 |
| Mar 31, 2014 | 141,000.00 |
| Dec 31, 2013 | -4,000.00 |
| Dec 31, 2013 | -4,000.00 |
| Sep 30, 2013 | -3,000.00 |
| Sep 30, 2013 | -3,000.00 |